(ALNY) Alnylam Pharmaceuticals - Overview
Stock: Rna Therapeutics, Amyloidosis Drugs, Cardiometabolic Agents
| Risk 5d forecast | |
|---|---|
| Volatility | 42.4% |
| Relative Tail Risk | -16.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.79 |
| Alpha | 21.44 |
| Character TTM | |
|---|---|
| Beta | 0.892 |
| Beta Downside | 1.020 |
| Drawdowns 3y | |
|---|---|
| Max DD | 37.20% |
| CAGR/Max DD | 0.57 |
EPS (Earnings per Share)
Revenue
Primary Risks
P/E ratio: 144.9095
Description: ALNY Alnylam Pharmaceuticals January 29, 2026
Alnylam Pharmaceuticals (NASDAQ: ALNY) is a U.S. biotech that builds its business on RNA-interference (RNAi) therapeutics. Its commercial portfolio includes ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis, GIVLAARI for acute hepatic porphyria, OXLUMO for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. The firm is advancing a broad pipeline of RNAi candidates across multiple disease areas, with at least nine programs in late-stage trials (e.g., vutrisiran for ATTR-cardiomyopathy, Fitusiran for hemophilia, and cemdisiran for Myasthenia Gravis).
The pipeline also contains early-stage assets targeting hypertension (Zilebesiran), metabolic-associated steatohepatitis (Rapirosiran), type 2 diabetes (ALN-4324), dyslipidemia (ALN-APOC3), and neurodegenerative disorders such as Huntington’s disease (ALN-HTT02). Alnylam leverages a network of collaborations with major pharma partners-including Regeneron, Roche, Sanofi, Novartis, and Ionis-to co-develop and commercialize RNAi drugs, which helps diversify risk and expand market reach.
As of the Q4 2023 earnings release (Feb 2024), Alnylam reported revenue of $1.02 billion, a 27 % YoY increase driven primarily by Leqvio sales, while R&D expense rose 15 % to $560 million, reflecting late-stage trial activity. The company’s cash runway extends beyond 2026 at current burn rates, and its market capitalization sits near $12 billion, positioning it among the larger RNAi players. Industry analysts note that the RNAi market is projected to grow at a CAGR of ~12 % through 2030, supported by expanding FDA approvals and payer acceptance of gene-silencing therapies-key macro drivers that could amplify Alnylam’s upside if its late-stage candidates succeed.
For a deeper quantitative assessment of how these catalysts translate into valuation risk/reward, you may want to explore the company’s profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 313.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 10.38 > 1.0 |
| NWC/Revenue: 69.58% < 20% (prev 93.81%; Δ -24.22% < -1%) |
| CFO/TA 0.11 > 3% & CFO 524.1m > Net Income 313.7m |
| Net Debt (-378.9m) to EBITDA (472.7m): -0.80 < 3 |
| Current Ratio: 2.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (136.3m) vs 12m ago 5.98% < -2% |
| Gross Margin: 81.72% > 18% (prev 0.86%; Δ 8086 % > 0.5%) |
| Asset Turnover: 80.68% > 50% (prev 53.02%; Δ 27.66% > 0%) |
| Interest Coverage Ratio: 1.65 > 6 (EBITDA TTM 472.7m / Interest Expense TTM 252.6m) |
Altman Z'' -2.07
| A: 0.52 (Total Current Assets 4.05b - Total Current Liabilities 1.47b) / Total Assets 4.97b |
| B: -1.35 (Retained Earnings -6.70b / Total Assets 4.97b) |
| C: 0.09 (EBIT TTM 417.0m / Avg Total Assets 4.60b) |
| D: -1.61 (Book Value of Equity -6.72b / Total Liabilities 4.18b) |
| Altman-Z'' Score: -2.07 = D |
Beneish M -2.60
| DSRI: 1.16 (Receivables 777.6m/405.3m, Revenue 3.71b/2.25b) |
| GMI: 1.05 (GM 81.72% / 85.62%) |
| AQI: 0.71 (AQ_t 0.04 / AQ_t-1 0.06) |
| SGI: 1.65 (Revenue 3.71b / 2.25b) |
| TATA: -0.04 (NI 313.7m - CFO 524.1m) / TA 4.97b) |
| Beneish M-Score: -2.60 (Cap -4..+1) = A |
What is the price of ALNY shares?
Over the past week, the price has changed by +1.08%, over one month by -9.14%, over three months by -22.58% and over the past year by +35.05%.
Is ALNY a buy, sell or hold?
- StrongBuy: 12
- Buy: 12
- Hold: 7
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the ALNY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 457 | 35.9% |
| Analysts Target Price | 457 | 35.9% |
ALNY Fundamental Data Overview February 22, 2026
P/E Forward = 46.5116
P/S = 12.0052
P/B = 57.032
P/EG = -0.49
Revenue TTM = 3.71b USD
EBIT TTM = 417.0m USD
EBITDA TTM = 472.7m USD
Long Term Debt = 1.01b USD (from longTermDebt, last quarter)
Short Term Debt = 45.5m USD (from shortTermDebt, last quarter)
Debt = 1.28b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -378.9m USD (from netDebt column, last quarter)
Enterprise Value = 42.96b USD (44.59b + Debt 1.28b - CCE 2.91b)
Interest Coverage Ratio = 1.65 (Ebit TTM 417.0m / Interest Expense TTM 252.6m)
EV/FCF = 92.30x (Enterprise Value 42.96b / FCF TTM 465.4m)
FCF Yield = 1.08% (FCF TTM 465.4m / Enterprise Value 42.96b)
FCF Margin = 12.53% (FCF TTM 465.4m / Revenue TTM 3.71b)
Net Margin = 8.45% (Net Income TTM 313.7m / Revenue TTM 3.71b)
Gross Margin = 81.72% ((Revenue TTM 3.71b - Cost of Revenue TTM 678.9m) / Revenue TTM)
Gross Margin QoQ = 75.60% (prev 84.21%)
Tobins Q-Ratio = 8.65 (Enterprise Value 42.96b / Total Assets 4.97b)
Interest Expense / Debt = 10.12% (Interest Expense 129.3m / Debt 1.28b)
Taxrate = 2.91% (9.40m / 323.2m)
NOPAT = 404.9m (EBIT 417.0m * (1 - 2.91%))
Current Ratio = 2.76 (Total Current Assets 4.05b / Total Current Liabilities 1.47b)
Debt / Equity = 1.62 (Debt 1.28b / totalStockholderEquity, last quarter 789.2m)
Debt / EBITDA = -0.80 (Net Debt -378.9m / EBITDA 472.7m)
Debt / FCF = -0.81 (Net Debt -378.9m / FCF TTM 465.4m)
Total Stockholder Equity = 347.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.82% (Net Income 313.7m / Total Assets 4.97b)
RoE = 90.35% (Net Income TTM 313.7m / Total Stockholder Equity 347.3m)
RoCE = 30.78% (EBIT 417.0m / Capital Employed (Equity 347.3m + L.T.Debt 1.01b))
RoIC = 29.50% (NOPAT 404.9m / Invested Capital 1.37b)
WACC = 9.22% (E(44.59b)/V(45.86b) * Re(9.20%) + D(1.28b)/V(45.86b) * Rd(10.12%) * (1-Tc(0.03)))
Discount Rate = 9.20% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.92%
[DCF Debug] Terminal Value 64.91% ; FCFF base≈465.4m ; Y1≈305.5m ; Y5≈139.4m
Fair Price DCF = 19.83 (EV 2.25b - Net Debt -378.9m = Equity 2.63b / Shares 132.6m; r=9.22% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 78.40 | EPS CAGR: 53.70% | SUE: 0.02 | # QB: 0
Revenue Correlation: 92.33 | Revenue CAGR: 54.77% | SUE: -0.55 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.59 | Chg30d=-0.750 | Revisions Net=-3 | Analysts=11
EPS current Year (2026-12-31): EPS=9.56 | Chg30d=-1.677 | Revisions Net=-1 | Growth EPS=+88.2% | Growth Revenue=+50.3%
EPS next Year (2027-12-31): EPS=14.54 | Chg30d=-3.310 | Revisions Net=-2 | Growth EPS=+52.1% | Growth Revenue=+30.5%